|
advertisement
|
news roundup
A consortium of healthcare companies have announced the launch of the COVID-19 Research Database, a secure repository of HIPAA-compliant, de-identified and limited patient-level data sets made available to public health and policy researchers to extract insights to help combat the COVID-19 pandemic.
Medable announces a multi-company research framework to accelerate development of diagnostics and treatments for COVID-19. The ACCESS initiative—short for American COVID-19 Collaborative Enabling Seamless Science—provides a mobile consumer application and secure infrastructure to connect health researchers and clinical trial teams securely with up to millions of home-bound individuals in the United States.
ERT has announced a partnership with AliveCor to enable ERT to capture digital cardiac safety data with KardiaMobile 6L, the only FDA-cleared personal ECG for patient-administered 6-lead data collection.
There is still time to register and participate in the virtual The 2nd Annual Medical Hero Appreci-a-thon to express appreciation for all “Medical Heroes”—medical and healthcare professionals, researchers and study volunteers.
|
|
|
Subscribe
 |
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »
|
|
|
|
|
|
|
|
|
Articles |
|
In this paper, the authors show a risk-based portfolio simulation that helps uncover the probabilities of a COVID-19 vaccine being approved within a certain number of months or the expectations of managing a global vaccine portfolio approach vs. a company-level or national-level approach using decision support analysis.
|
|
Clinical SCORE’s recent survey of clinical trial sites show of effects from the pandemic show a dedication to ongoing trials at the site level, but help, guidance and understanding from sponsors and CROs are needed and outlined in this article.
|
|
|
Blog Posts
The National Institutes of Health announced a broad public-private partnership to collaborate on prioritizing and coordinating research on COVID-19 drug and vaccine candidates. The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative has support from a number of federal agencies, and some 16 pharma and biotech companies are participating through the Foundation for the National Institutes of Health.
The EMA’s activities addressing COVID-19 include the creation of a pandemic task force to manage and coordinate discussions on relevant product development, authorization and surveillance, as well as updated guidance for pharmaceutical companies on developing therapies during the pandemic.
|
|
|
|
|
|
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription
|
|
|
|
|
|
